RAMMURTI KAMBLE to Multiple Myeloma
This is a "connection" page, showing publications RAMMURTI KAMBLE has written about Multiple Myeloma.
Connection Strength
3.114
-
Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma. Bone Marrow Transplant. 2014 Feb; 49(2):219-22.
Score: 0.375
-
Diffuse pulmonary parenchymal involvement in multiple myeloma: antemortem diagnosis. Int J Hematol. 2006 Apr; 83(3):259-61.
Score: 0.223
-
Malignant pleural effusion of multiple myeloma: prognostic factors and outcome. Leuk Lymphoma. 2005 Aug; 46(8):1137-42.
Score: 0.213
-
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022 07 14; 387(2):132-147.
Score: 0.171
-
Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study. Leuk Lymphoma. 2021 12; 62(13):3256-3263.
Score: 0.161
-
Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. Br J Haematol. 2020 11; 191(3):442-452.
Score: 0.153
-
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. Cancer. 2021 01 01; 127(1):82-92.
Score: 0.152
-
The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Sci Transl Med. 2020 07 29; 12(554).
Score: 0.150
-
Safety Analysis of Five Randomized Controlled Studies of Daratumumab in Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2020 09; 20(9):e579-e589.
Score: 0.148
-
Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. Biol Blood Marrow Transplant. 2019 04; 25(4):683-688.
Score: 0.135
-
Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. Biol Blood Marrow Transplant. 2018 12; 24(12):2443-2449.
Score: 0.131
-
Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. Cancer. 2017 05 15; 123(10):1828-1838.
Score: 0.118
-
Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Feb; 23(2):269-277.
Score: 0.116
-
Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2015 Dec; 50(12):1513-8.
Score: 0.107
-
New cancers after autotransplantations for multiple myeloma. Biol Blood Marrow Transplant. 2015 Apr; 21(4):738-45.
Score: 0.102
-
Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2014 Mar; 20(3):402-408.e1.
Score: 0.095
-
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant. 2013 Nov; 19(11):1615-24.
Score: 0.093
-
Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant. 2013 May; 19(5):760-6.
Score: 0.089
-
Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. Bone Marrow Transplant. 2012 Jun; 47(6):831-7.
Score: 0.081
-
Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood. 2011 Aug 18; 118(7):1979-88.
Score: 0.080
-
Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1765-74.
Score: 0.079
-
Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2010 Mar; 16(3):395-402.
Score: 0.072
-
Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. Leuk Res. 2010 Jan; 34(1):85-92.
Score: 0.070